IL151690A0 - Medicaments for complications of diabetes and neuropathy, and uses thereof - Google Patents

Medicaments for complications of diabetes and neuropathy, and uses thereof

Info

Publication number
IL151690A0
IL151690A0 IL15169001A IL15169001A IL151690A0 IL 151690 A0 IL151690 A0 IL 151690A0 IL 15169001 A IL15169001 A IL 15169001A IL 15169001 A IL15169001 A IL 15169001A IL 151690 A0 IL151690 A0 IL 151690A0
Authority
IL
Israel
Prior art keywords
neuropathy
medicaments
complications
diabetes
Prior art date
Application number
IL15169001A
Other languages
English (en)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of IL151690A0 publication Critical patent/IL151690A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15169001A 2000-03-17 2001-03-15 Medicaments for complications of diabetes and neuropathy, and uses thereof IL151690A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000076542 2000-03-17
PCT/JP2001/002094 WO2001068136A1 (fr) 2000-03-17 2001-03-15 Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments

Publications (1)

Publication Number Publication Date
IL151690A0 true IL151690A0 (en) 2003-04-10

Family

ID=18594265

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15169001A IL151690A0 (en) 2000-03-17 2001-03-15 Medicaments for complications of diabetes and neuropathy, and uses thereof

Country Status (20)

Country Link
US (1) US20030073729A1 (zh)
EP (1) EP1283054A4 (zh)
KR (2) KR100873585B1 (zh)
CN (2) CN1768735A (zh)
AU (2) AU4116801A (zh)
BR (1) BR0109336A (zh)
CA (1) CA2403442A1 (zh)
CZ (1) CZ20023121A3 (zh)
HK (1) HK1055674A1 (zh)
HU (1) HUP0300325A3 (zh)
IL (1) IL151690A0 (zh)
MX (1) MXPA02009130A (zh)
NO (1) NO20024429L (zh)
NZ (1) NZ521366A (zh)
PL (1) PL357719A1 (zh)
RU (1) RU2281764C2 (zh)
SK (1) SK14922002A3 (zh)
TW (1) TWI305726B (zh)
WO (1) WO2001068136A1 (zh)
ZA (1) ZA200207223B (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
CN1232502C (zh) * 2000-10-18 2005-12-21 味之素株式会社 那格列胺结晶的制备方法
AU2001296000A1 (en) * 2000-10-24 2002-05-27 Ajinomoto Co., Inc. Nateglinide-containing hydrophilic drug preparations
WO2002034713A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Procede de production de cristaux de nateglinide a forme b
EP1334720B1 (en) * 2000-10-24 2008-09-03 Ajinomoto Co., Inc. Nateglinide-containing preparations
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
PT1547614E (pt) * 2002-05-28 2011-04-06 Ajinomoto Kk Composição medicinal para inibir a expressão de atp-citrato liase e sua utilização
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
EP1532979A4 (en) * 2002-06-28 2008-01-16 Kissei Pharmaceutical DRUG COMPOSITION FOR REGULATING GLYCEMIA
US20050215607A1 (en) * 2002-06-28 2005-09-29 Imao Mikoshiba Drug composition for prevention or inhibition of advance of diabetic complication
EP1602652A1 (en) * 2003-03-03 2005-12-07 San-Ei Gen F.F.I., Inc. Adiponectin expression promoter
EP2474328A3 (en) * 2003-09-17 2012-07-18 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
WO2005049006A1 (ja) * 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
TW200626163A (en) * 2004-09-22 2006-08-01 Kureha Corp Agent for treating or preventing diabetic neuropathy
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
CN1947794B (zh) * 2005-10-16 2010-09-01 安徽省现代中药研究中心 含有磺酰脲类和苯氧酸类化合物的药物组合物
JP2009514896A (ja) * 2005-11-07 2009-04-09 エリクシアー ファーマシューティカルズ， インコーポレイテッド メトホルミンおよびメグリチニドの組み合わせ
EP2285374B1 (en) * 2008-04-29 2019-09-18 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CN102083854A (zh) * 2008-06-17 2011-06-01 大塚化学株式会社 附加了糖链的glp-1肽
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
PT2424356T (pt) 2009-04-29 2017-11-23 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
NZ620473A (en) 2009-06-15 2015-09-25 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
IT1398168B1 (it) * 2010-02-16 2013-02-14 Chiesi Farma Spa Uso di ingredienti attivi in combinazione per il trattamento delle complicanze del diabete.
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013115739A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Production method for formulations comprising comprising nateglinide and lipoic acid
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3750536A1 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444756A1 (es) * 1975-01-31 1977-08-16 Ciba Geigy Procedimiento para la obtencion de compuestos basicos insa- turados.
JPS5938960B2 (ja) * 1979-10-12 1984-09-20 呉羽化学工業株式会社 アミノ安息香酸エステル誘導体及び該誘導体を含有する医薬
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
JP2634450B2 (ja) * 1988-11-11 1997-07-23 株式会社サンギ 糖尿病用薬剤
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
IL113313A (en) * 1994-04-11 1999-09-22 Sankyo Co Heterocyclic compounds and pharmaceutical compositions containing the same
JPH08157462A (ja) * 1994-12-08 1996-06-18 Terumo Corp ジオキソチアゾリジン誘導体及びそれを含有する医薬組成物
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH08245602A (ja) * 1995-03-08 1996-09-24 Terumo Corp ジオキソチアゾリジン誘導体及びそれを有効成分とする医薬組成物
JPH0995445A (ja) * 1995-07-24 1997-04-08 Kanegafuchi Chem Ind Co Ltd 脳神経細胞障害に対する治療薬
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
EP2277517A1 (en) * 1996-11-15 2011-01-26 Ajinomoto Co., Inc. Nateglinide tablet composition
PT1011673E (pt) * 1997-06-13 2001-11-30 Novo Nordisk As Nova posologia para a dmni
EP1045898A2 (en) * 1998-01-12 2000-10-25 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6100300A (en) * 1998-04-28 2000-08-08 Bristol-Myers Squibb Company Metformin formulations and method for treating intermittent claudication employing same
AR028299A1 (es) * 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
ES2211454T3 (es) * 1999-09-30 2004-07-16 Pfizer Products Inc. Pirrolilamidas como inhibidores de la colageno fosforilasa.
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1239854A1 (en) * 1999-12-23 2002-09-18 Novartis AG Use of a hypoglycemic agent for treating impaired glucose metabolism
ATE310507T1 (de) * 1999-12-28 2005-12-15 Ajinomoto Kk Orale zusammensetzungen für diabetes
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
CN1232502C (zh) * 2000-10-18 2005-12-21 味之素株式会社 那格列胺结晶的制备方法
WO2002034713A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Procede de production de cristaux de nateglinide a forme b
EP1334720B1 (en) * 2000-10-24 2008-09-03 Ajinomoto Co., Inc. Nateglinide-containing preparations
EP1345890A1 (en) * 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6652838B2 (en) * 2001-04-05 2003-11-25 Robert E. Weinstein Method for treating diabetes mellitus
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물

Also Published As

Publication number Publication date
KR100873585B1 (ko) 2008-12-11
CZ20023121A3 (cs) 2003-05-14
CN1768735A (zh) 2006-05-10
MXPA02009130A (es) 2003-03-12
AU2001241168B2 (en) 2005-06-16
TWI305726B (en) 2009-02-01
CA2403442A1 (en) 2002-09-17
CN1234414C (zh) 2006-01-04
KR20070104953A (ko) 2007-10-29
HK1055674A1 (en) 2004-01-21
ZA200207223B (en) 2003-09-09
HUP0300325A2 (hu) 2003-07-28
PL357719A1 (en) 2004-07-26
BR0109336A (pt) 2003-06-24
NZ521366A (en) 2005-07-29
HUP0300325A3 (en) 2004-08-30
EP1283054A1 (en) 2003-02-12
KR20020081459A (ko) 2002-10-26
NO20024429D0 (no) 2002-09-16
SK14922002A3 (sk) 2003-04-01
NO20024429L (no) 2002-11-06
EP1283054A4 (en) 2006-04-12
AU4116801A (en) 2001-09-24
RU2281764C2 (ru) 2006-08-20
US20030073729A1 (en) 2003-04-17
CN1418109A (zh) 2003-05-14
WO2001068136A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
IL151690A0 (en) Medicaments for complications of diabetes and neuropathy, and uses thereof
AU2001241168A1 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
AU2001295921A1 (en) Packaging material for electronic-part case, and others
EP1405859A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE, MEDICAL COMPOSITION, MEDICAL USE AND INTERMEDIATE PRODUCTS CONTAINING THEREOF
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
HUP0203885A3 (en) Novel tiotropium-containing inhalation powder, process for its preperation and its use
AU2682401A (en) Flavonoid drug and dosage form, its production and use
IL151496A0 (en) Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
HK1070055A1 (en) 5-Membered heterocycles, preparation and application thereof as medicaments
AU2001263360A1 (en) 50365, a hexokinase family member and uses thereof
AU2002214006A1 (en) Drugs for diabetes
AU2001267645A1 (en) Cyclic urea compounds and preparation thereof
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU2001294240A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
AU2001260110A1 (en) Novel LHRH-antagonists, Production and Use Thereof as Medicament
AU2001267135A1 (en) Medicaments
AU2001252046A1 (en) New bacteriocin, production and use thereof
AU2001241067A1 (en) Omega-substituted phenyl-prostaglandin e-alcohols, process for producing the same and drugs containing the same as the active ingredient
GB0109384D0 (en) Pharmaceutical products, preparation and uses thereof
AU2001266356A1 (en) Remedies for diabetes
AU2001262084A1 (en) Maurocalcine, analogues thereof and their therapeutical uses
AU2001251647A1 (en) 16051a and 16051b, novel human pdz family members and uses thereof
AU2001266201A1 (en) Medicaments
AU2002217119A1 (en) Carboxamides, medicaments containing said compounds, use and production thereof
MXPA03008636A (es) Derivados de isoquinuclidina, metodo para fabricar los mismos y agentes terapeuticos que contienen estos compuestos.